CBD-cancer Study Endorsed by UK’s National Cancer Research Institute

An upcoming clinical trial of CBD’s effects on cancer pain has been endorsed by the UK’s National Cancer Research Institute (NCRI).

The trial, run by the pharmaceutical company CBD Science Group, will assess how cannabinoids like CBD and THC can benefit patients living with cancer-related pain.

The trials’ new endorsement comes from the NCRI’s Living With and Beyond Cancer (LWBC) executive group.

“We are delighted and proud to have been offered this endorsement from the NCRI LWBC, which offers hope to millions of people with long term cancer pain around the world,” Graeme McFarlane, CBD Science Group’s chief commercial officer, said in a statement.

“This partnership will further progress CBD Science Group towards our objective of realising the advantages of cannabinoids in fulfilling this urgent need of suffering patients. We strongly believe in the opportunity that our RWE [real world evidence] study presents, and look forward to working closely and deepening our relationship with the NCRI.”

The trial is due to begin next year.